- Home
- SNDX vs BRKL Comparison
SNDX vs BRKL Comparison
Compare SNDX & BRKL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- BRKL
- Stock Information
- Founded
- SNDX 2005
- BRKL 1871
- Country
- SNDX United States
- BRKL United States
- Employees
- SNDX N/A
- BRKL N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- BRKL Savings Institutions
- Sector
- SNDX Health Care
- BRKL Finance
- Exchange
- SNDX Nasdaq
- BRKL Nasdaq
- Market Cap
- SNDX 1.1B
- BRKL 944.5M
- IPO Year
- SNDX 2016
- BRKL 1998
- Fundamental
- Price
- SNDX $9.60
- BRKL $11.00
- Analyst Decision
- SNDX Strong Buy
- BRKL Buy
- Analyst Count
- SNDX 11
- BRKL 2
- Target Price
- SNDX $34.18
- BRKL $15.25
- AVG Volume (30 Days)
- SNDX 2.0M
- BRKL 574.6K
- Earning Date
- SNDX 07-31-2025
- BRKL 07-23-2025
- Dividend Yield
- SNDX N/A
- BRKL 4.83%
- EPS Growth
- SNDX N/A
- BRKL N/A
- EPS
- SNDX N/A
- BRKL 0.82
- Revenue
- SNDX $43,722,000.00
- BRKL $338,567,000.00
- Revenue This Year
- SNDX $426.77
- BRKL $53.95
- Revenue Next Year
- SNDX $98.31
- BRKL $68.33
- P/E Ratio
- SNDX N/A
- BRKL $13.63
- Revenue Growth
- SNDX N/A
- BRKL N/A
- 52 Week Low
- SNDX $8.58
- BRKL $8.84
- 52 Week High
- SNDX $25.07
- BRKL $13.15
- Technical
- Relative Strength Index (RSI)
- SNDX 48.99
- BRKL 57.33
- Support Level
- SNDX $8.59
- BRKL $11.07
- Resistance Level
- SNDX $10.01
- BRKL $11.31
- Average True Range (ATR)
- SNDX 0.54
- BRKL 0.25
- MACD
- SNDX 0.10
- BRKL 0.06
- Stochastic Oscillator
- SNDX 71.48
- BRKL 72.34
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
About BRKL Brookline Bancorp Inc.
Brookline Bancorp Inc operates as a multi-bank holding company. It offers commercial, business, and retail banking services, including a full complement of cash management products, online banking services, and consumer and residential loans.